

Pt(II)-Catalyzed Synthesis of 1,2-Dihydropyridines from Aziridinyl Propargylic Esters


Massoud Motamed, Eric M. Bunnelle, Surendra W. Singaram, and Richmond Sarpong*

Department of Chemistry, University of California, Berkeley, California 94720

rsarpong@berkeley.edu

Received March 20, 2007

ABSTRACT



Pt(II)-catalyzed cycloisomerization of aziridinyl propargylic esters affords 1,2-dihydropyridines with regiodefined installation of substituents. A mild conversion of the 1,2-dihydropyridines to the corresponding substituted pyridines as well as chirality retention from the aziridinyl propargylic ester substrates have been demonstrated.

Nitrogen-containing heterocycles comprise a large percentage of natural products and pharmaceutically important small molecules.¹ Methods directed toward the synthesis of aza-heterocycles continue to be an important undertaking, and general strategies for the regio- and stereocontrolled introduction of substituents remain a challenge. Dihydropyridines (DHPs) have long been recognized as versatile synthetic intermediates² that provide ready access to a variety of substituted nitrogen-containing heterocycles such as piperidines (by reduction)³ or to pyridines (by oxidation).⁴ Historically, 1,4-dihydropyridines (1,4-DHPs) have been the most studied, whereas 1,2-DHPs have received relatively little attention. This has stemmed primarily from the ease with which these compounds can be accessed from pyridinium salts by nucleophilic addition at C(4) and the emergence of Hantzsch-type 1,4-DHPs as important calcium channel blockers.⁵ The majority of synthetic approaches to 1,2-DHPs has also relied

on nucleophilic addition into *N*-alkyl or *N*-acylpyridinium salts.^{6,7} Unfortunately, regioisomeric mixtures of addition products (at the 2, 4, or 6 position) are often obtained if unsymmetrically substituted pyridinium salts, especially those that do not bear a substituent at the C(4) position, are employed.⁸ More recently, other strategies for the synthesis of 1,2-DHPs have emerged that address some of these limitations.⁹ Because of the lack of general methods for the regioselective synthesis of highly functionalized 1,2-DHP derivatives, their synthetic and biological potential remains largely unexplored. As such, there is a continued need for the development of more functional-group-tolerant methods that avoid the use of organolithium or Grignard reagents to access 1,2-DHPs as well as general strategies that afford access to bicyclic 1,2-DHPs.

We envisioned that 1,2-DHPs (e.g., **5a**, Scheme 1) could be realized from aziridinyl propargylic esters (see **1a**) via a

(1) (a) Cordell, A. B. *The Alkaloids: Chemistry and Biology*; Elsevier Science: San Diego, CA, 2003; Vol. 60. (b) Hesse, M. *Alkaloids: Nature's Curse or Blessing?*; WILEY-VCH: Weinheim, 2003.

(2) Lavilla, R. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1141–1156.

(3) For an example, see: Charette, A. B.; Grenon, M.; Lemire, A.; Pourashraf, M.; Martel, J. *J. Am. Chem. Soc.* **2001**, *123*, 11829–11830.

(4) Chai, L. Z.; Zhao, Y. K.; Sheng, Q. J.; Liu, Z.-Q. *Tetrahedron Lett.* **2006**, *47*, 9283–9285.

(5) For a review, see: Gaudio, A. C.; Korolkovas, A.; Takahata, Y. *J. Pharm. Sci.* **1994**, *83*, 1110–1115.


(6) For a review, see: Stout, D. M.; Meyers, A. I. *Chem. Rev.* **1982**, *82*, 233–243.

(7) Comins, D. L.; Hong, H.; Salvador, J. M. *J. Org. Chem.* **1991**, *56*, 7197–7199. See also ref 3.

(8) For examples, see: (a) Sundberg, R. J.; Hamilton, G.; Trindle, C. *J. Org. Chem.* **1986**, *51*, 3672–3679. (b) Bannasar, M. L.; Roca, R.; Monerri, M.; Juan, C.; Bosch, J. *Tetrahedron* **2002**, *58*, 8099–8106.

(9) (a) Ichikawa, E.; Suzuki, M.; Yabu, K.; Albert, M.; Kanai, M.; Shibasaki, M. *J. Am. Chem. Soc.* **2004**, *126*, 11808–11809. (b) Brunner, B.; Stogaitis, N.; Lautens, M. *Org. Lett.* **2006**, *8*, 3473–3476.


Scheme 1. Proposed Formation of 1,2-Dihydropyridines



Pt(II)-catalyzed cascade sequence. Thus, formation of zwitterion **2** from **1a** via a 5-*exo*-dig cyclization of the ester carbonyl functionality onto the alkyne and subsequent rearrangement could afford metalcarbenoid **3**. The strained [3.1.0] bicyclic **4** could then result from nucleophilic attack of the aziridinyl nitrogen on the metalcarbenoid functionality. At this stage, irreversible valence bond isomerization coupled with the strain-release fragmentation of the aziridine was expected to produce 1,2-DHP **5a**.

The expectation that **5a** could be formed from **1a** is supported by our recent report of a Pt(II)-catalyzed method for the synthesis of acyloxycyclopentenones (e.g., **9**, Scheme 2) using epoxide-bearing propargylic ester substrates (**6**).¹⁰

Scheme 2. Epoxide Fragmentation/Pentannulation Reaction



Our earlier investigations on the formation of **9** from **6** support a mechanism involving the intermediacy of 3(2*H*)-pyran **7** and oxatriene **8**. However, unlike 3(2*H*)-pyrans, which are prone to oxa-6 π -electrocyclic ring opening¹¹ and usually exist in equilibrium with the dienone or dienal valence bond isomer, 1,2-DHPs are relatively robust. As such, we hoped to identify optimal conditions for their synthesis from aziridinyl propargylic esters without competing ring-opening reactions.

To test the viability of our approach to 1,2-DHPs, a judicious choice of protecting group had to be made to

(10) Pujanauski, B. G.; Prasad, B. A. B.; Sarpong, R. *J. Am. Chem. Soc.* **2006**, *128*, 6786–6787.

(11) For a discussion of pyran chemistry, see: *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Rees, C. W., Eds.; Pergamon: Oxford, 1984; Vol. 3, pp 737–874.

overcome the following challenges: (1) oxidation of dihydropyridines in the presence of air;¹² (2) the nucleophilicity of the aziridine nitrogen had to be tempered to allow for an initial interaction of the activated Pt(II)-bound alkyne and the propargylic ester (see **1a**→**2**) without competing nitrogen addition to the alkyne;¹³ and (3) the reactivity of the aziridine nitrogen had to be tuned to allow for its addition to the metalcarbenoid functionality of **3** to afford **4** en route to **5a**. Importantly, this addition should be rapid relative to a potential vinyl aziridine rearrangement of **3**.¹⁴

Table 1. Pt(II)-Catalyzed 1,2-Dihydropyridine Synthesis^a

entry	substrate	product	yield(%) ^b
1			
	a) R = Me		76
	b) R = <i>p</i> -ClPh		72
	c) R = <i>t</i> Bu		76
	d) R = Ph		76
2			56
3			
	a) R = cyclopropyl		62
	b) R = Ph		69
	c) R = H		70
4			76

^a Standard conditions: 10 mol % of PtCl₂, 0.2 M in PhMe at 100 °C over 3 h. ^b Isolated yields after column chromatography are reported.

The aziridinyl propargylic ester substrates (see Table 1) were prepared by acylation of the corresponding aziridine propargylic alcohols, which were available from the aziridinyl aldehyde via a highly diastereoselective (>95:5 dr) 1,2-

(12) Olah, G. A.; Hunadi, R. *J. Org. Chem.* **1981**, *46*, 715–718.

(13) We have recently described that other nitrogen nucleophiles (e.g., pyridinyl nitrogens) add faster to activated alkynes relative to the propargylic carboxylate. See: Smith, C. R.; Bunnelle, E. M.; Rhodes, A. J.; Sarpong, R. *Org. Lett.* **2007**, *9*, 1169–1171.


(14) For a recent discussion of vinyl aziridine rearrangements, see: Ohno, H. In *Aziridines and Epoxides in Organic Synthesis*; Yudin, A. K., Ed.; WILEY-VCH: Weinheim, 2006; pp 37–72.

addition¹⁵ of the corresponding alkynyllithium or Grignard.¹⁶ We were gratified to find that under Pt(II) catalysis (10 mol % of PtCl₂, 0.2 M in PhMe, 100 °C, 3 h) a range of aziridinyl propargylic esters afforded the expected 1,2-DHP products in moderate to good yields.

As shown in Table 1, acetates, *para*-chlorobenzoate, pivalate, and benzoate propargylic esters can be employed (entries 1a–d). The permissibility of the nucleophile at the propargylic position is further highlighted by the reaction of trichloroacetimidate **10** (entry 2) to afford **11** in 56% yield. To the best of our knowledge, this constitutes the first report of the use of a trichloroacetimidate in a Pt(II)-catalyzed cycloisomerization reaction.¹⁷ In addition, internal alkynes bearing cyclopropyl or phenyl substituents at the alkyne terminus (entries 3a and b, respectively) as well as cyclic substrates (entry 4) readily participate in this transformation to give good isolated yields (62–76%) of the desired 1,2-DHP product.

In an effort to expand the scope of the substrates that participate in this reaction, other substituents at the aziridine nitrogen were explored. The *N*-acyl substrates (**16a–d**, Scheme 3) were considered in a preliminary study.¹⁶ On the

Scheme 3. Pt(II)-Catalyzed Cycloisomerization of Acylated Aziridine Substrates



entry	substrate (16)	yield of 17 [%]
1	a) R = Me	71
2	b) R = Ph	74
3	c) R = <i>p</i> -Tol	69
4	d) R = <i>p</i> -ClPh	65

basis of literature precedent, which highlights the ambident nucleophilicity of acylated aziridines,¹⁸ we hypothesized that the presumed metallocarbenoid intermediate could lead to 1,2-DHP **17** or amide-incorporated heterocycle **18** products. Although **17** would arise via the initially proposed mechanism in which the aziridine nitrogen engages the metallocarbenoid intermediate (Scheme 1), **18** could be formed through a pathway involving the nucleophilic addition of the *N*-acyl carbonyl to the metallocarbenoid intermediate.¹⁹

(15) A chelation-controlled 1,2-addition initially proposed to explain the high diastereoselectivity has recently been called into question. See: (a) Righi, G.; Piertrantonio, S.; Bonini, C. *Tetrahedron* **2001**, *57*, 10039–10046. And: (b) Schomaker, J. M.; Geiser, A. R.; Huang, R.; Borhan, B. *J. Am. Chem. Soc.* **2007**, *129*, 3794–3795.

(16) See Supporting Information for a detailed description for the synthesis of the substrates.

(17) PtCl₂ has been used to catalyze the Overman rearrangement of trichloroacetimidates. See: Jaunzeme, I.; Jirgensons, A. *Synlett* **2005**, 2984–2986.

(18) Mente, P. G.; Heine, H. W.; Scharoubim, G. R. *J. Org. Chem.* **1968**, *33*, 4547–4548.

As detailed in Scheme 3, several acylated aziridines were subjected to the standard reaction conditions and yielded the 1,2-DHPs (**17a–d**) as the major product after column chromatography (65–74% yield). An X-ray crystal structure of 1,2-DHP **17c** (Figure 1)²⁰ provides further support for the





Figure 1. ORTEP structure of 1,2-dihydropyridine **17c** with ellipsoids shown at the 50% probability level.

assigned structure of the 1,2-DHP products that result from the preferred mode of cyclization of the *N*-acyl aziridine substrates.

Under the standard reaction conditions, the Pt(II)-catalyzed transformation of substrates possessing alkyl substitution on the aziridine nitrogen (e.g., benzyl) has led to complex mixtures of products from which none of the desired 1,2-DHPs could be isolated. Presumably, the enhanced basicity of the aziridine lone pair leads to competing nonproductive pathways. This supports our identification of the aziridine protecting group as an important parameter in the design of substrates for this reaction.²¹


Although ample literature precedent exists for the conversion of 1,2-DHPs to pyridines, the conditions required for these processes often involve the use of strong oxidants or acids.²² We envisioned that our 1,2-DHP products may provide a suitable synthetic starting point to highly substituted pyridines under mild conditions. In a preliminary study, **5b** was readily converted in 79% yield to hydroxy pyridine **20** upon treatment with potassium trimethylsilanoate (TMSOK) at room temperature over 3 h (Scheme 4). Access to **20** now sets the stage for further functionalization (e.g., by activation of the hydroxyl group by triflation, followed by organo-metallic coupling).

(19) Mechanistically, this could proceed as illustrated below.




(20) Crystallographic data have been deposited in the Cambridge Crystallographic Data Centre (CCDC #637309). Refinement data are provided in the Supporting Information.

(21) The possibility of reduced stability of *N*-alkyl 1,2-dihydropyridines relative to *N*-tosyl or *N*-acyl 1,2-dihydropyridines under the reaction conditions may also contribute to the lack of success of this reaction.

Scheme 4. Conversion of 1,2-Dihydropyridines to Pyridines

We next investigated chirality retention in converting the aziridinyl propargylic ester substrates to the 1,2-DHP products. As shown in Scheme 5, enantiopure **1a**²³ is

Scheme 5. Chirality Retention in the Formation of 1,2-Dihydropyridines

transformed in 70% yield with only a minor loss of enantiomeric excess to the corresponding highly enantioenriched 1,2-DHP **5a**.

This result attests to the stability of the 1,2-DHP compounds toward epimerization (e.g., via subsequent ring-

(22) For a recent example, see: Lemire, A.; Grenon, M.; Pourashraf, M.; Charette, A. B. *Org. Lett.* **2004**, *6*, 3517–3520.

(23) Enantiopure **1a** was obtained by preparative chiral column HPLC of the racemate. For more information, see the Supporting Information.

opening/ring-closing processes) under our reaction conditions. With access to highly enantioenriched 1,2-DHPs now defined, the diastereoselective functionalization of these compounds should provide stereoselective access to a range of important azaheterocycles. These efforts are currently under investigation.

In conclusion, we report a novel Pt(II)-catalyzed cycloisomerization strategy for the synthesis of 1,2-DHPs that achieves the regiodefined installation of substituents using readily prepared aziridinyl propargylic ester substrates. In addition, a mild conversion of the 1,2-DHPs to the corresponding substituted pyridines as well as high levels of chirality retention from the aziridinyl propargylic ester substrates have been demonstrated. Efforts to further expand the scope of these transformations to include other examples of chirality retention and the identification of other modes of cyclization of the aziridinyl propargylic ester substrates are underway in our laboratories.

Acknowledgment. The authors are grateful to UC Berkeley, GlaxoSmithKline, Johnson Matthey, and Boehringer-Ingelheim for support of this research and to Ms. Christina Kraml (AccelaPure Corp., Frick Lab Rm 201, Princeton University, Princeton, NJ 08544) for enantiopure samples of **5a**. The authors also thank Drs. Fred Hollander and Hye Jin Choi (UC Berkeley) for crystallographic data.

Supporting Information Available: Experimental details and characterization data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL070658I